Severe Coronary Artery Disease Clinical Trial
Official title:
RANOLAZINE STUDY: The Effect of Ranolazine on Speckle Tracking Derived Myocardial Strain in Regions of Non-Revascularizable Ischemic Myocardium
The purpose of this study is to collect data to determine if the medication, Ranolazine, effects heart muscle function in patients who have areas of non-revascularizable heart muscle.
Many cardiac patients with severe coronary artery disease have areas of ischemic LV
myocardium that cannot be revascularized (Non-R). The investigators propose to identify such
patients via retrospective case review of CMRI data, as well as identify the exact regions
which specify Non-R coronary anatomy. This selected study group will have a specific
echocardiographic imaging protocol performed, which includes the known ischemic regions. All
segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE
software to derive strain values. Following eight (8) weeks of ranolazine therapy, each
subject will be re-interrogated with the same echocardiographic imaging protocol and have
identical measurements of regional strain performed. Ranolazine will be added to the
patients' usual medical therapy. Each patient will serve as their own control, from baseline
to post therapeutic state.
It is the hypothesis of the investigators, that additional therapeutic dosing of ranolazine
will improve regional and perhaps global myocardial function. Improvement in LV mechanical
function (regional and global) will be quantitated and objectively elucidated by STE derived
myocardial strain as described further in this document.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00510705 -
Chronic Inflammatory Activation in Fat Tissue: An Atherogenic Factor in Severe Coronary Artery Disease
|
N/A |